POMICELL

Company Overview

Snapshot

Founded in October 2016 by Boaz Buchandler, POMICELL operated with 1–10 employees. The company raised $4 million across three funding rounds. In January 2022, POMICELL appointed a new Chief Executive Officer.

Business overview

POMICELL develops POMI, an AI SaaS solution designed to enhance R&D processes for biomedical researchers. Its platform offers AI-based capabilities including automatic disease treatment, big data modeling, automatic mechanism of action, hypothesis creation from literature, and medical record-enhanced mechanism of action deciphering. The company aims to provide advanced digital tools to accelerate research and improve patient understanding within personalized medicine, operating in the Health Tech & Life Sciences sector.

Strategic signal

In January 2022, POMICELL appointed a new Chief Executive Officer, signaling a strategic leadership change aimed at guiding the company's future direction. This move indicates a focus on strengthening executive leadership to potentially navigate new market opportunities or operational challenges within the AI-driven personalized medicine space.

Company Intelligence Q&A

What is POMICELL's current operational status?

POMICELL is currently non-active and ceased to operate in June 2024.

When was POMICELL founded and by whom?

POMICELL was founded in October 2016 by Boaz Buchandler.

What is POMICELL's core product?

POMICELL's core product is POMI, an AI SaaS solution that enables biomedical researchers to create AI models for disease treatment, big data modeling, and mechanism of action deciphering.

What was a significant leadership change at POMICELL?

In January 2022, POMICELL appointed a new Chief Executive Officer.

Has POMICELL received any grants?

In January 2019, POMICELL secured a grant from the Israel Innovation Authority.